Loading AI tools
Vaccine candidate against COVID-19 From Wikipedia, the free encyclopedia
HGC019 is a mRNA and Self-amplifying mRNA (saRNA) based COVID-19 vaccine candidate being developed by Gennova Biopharmaceuticals and HDT Bio Corp. with active support from NIH under The Indo-US Vaccine Action Program (VAP) and Department of Biotechnology, India.[1]
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | mRNA |
Clinical data | |
Other names | HGCO19, Gemcovac, GEMCOVAC-19 |
Routes of administration | Intramuscular |
ATC code |
|
The phase-I trials began in February 2021 after receiving permission from Drugs Controller General of India (DGCI),[2][3] to evaluate the safety and immunogenicity of the vaccine candidate in about 120 participants consisting of age group (18–70) years.[4]
The phase-II trials is planned to conduct with 500 participants from the age group (18–75) years.[4] On 24 August 2021, the Drugs Controller General of India gave a go for phase II/III trials after it was found to be safe, tolerable, and immunogenic in the phase I trial results.[5][6][7]
The company has received a funding of ₹250 crore (around US$33.5 million) from Government of India based on the clinical trials progress.[8]
Seamless Wikipedia browsing. On steroids.
Every time you click a link to Wikipedia, Wiktionary or Wikiquote in your browser's search results, it will show the modern Wikiwand interface.
Wikiwand extension is a five stars, simple, with minimum permission required to keep your browsing private, safe and transparent.